上海市免疫治疗创新研究院成立于2021年,由上海市人民政府和上海交通大学共同建设。由国际著名免疫学家、中国科学院院士董晨教授领衔,依托上海交通大学医学院及其附属仁济医院进行系统性建设。研究院聚焦肿瘤免疫治疗、慢性炎症疾病与移植免疫、传染性疾病与疫苗等研发方向和应用领域,致力成为具有全球影响力的免疫创新策源地、免疫学领域的高端和关键人才的引育基地、国际一流的免疫学基础创新到产业应用的转化基地。
经过三年多的建设,研究院已形成扎实有效的人才引育体系,建成了设施完备的科研支撑平台;全职引进并实际到岗10名海内外优秀科学家,组建了一支资深和年轻学者相结合的高水平PI队伍;现有国家级人才(含青年人才)8位,并作为主要成员单位获批创新免疫治疗全国重点实验室。研究院继续面向海内外公开招聘高层次杰出人才,凝心聚力,同铸辉煌。
一、招聘方向
包括但不仅限于:
肿瘤免疫治疗
慢性炎症疾病与移植免疫
传染性疾病与疫苗
系统免疫学
二、基本任职条件
遵守中华人民共和国宪法和法律,品德高尚,学风严谨,身心健康。
具有博士学位,科研方向与研究院的发展布局相统一,在著名大学或研究机构从事研究工作,并已取得一流成就。
申报人应为所从事领域同龄人中的优秀人才,具有较高学术造诣,具有成为该领域领军人才的发展潜力,具备优良的团队统领能力,愿意参与交叉研究。
三、待遇
1.富有竞争力的协议薪酬和住房补贴;
2.提供良好的科研环境、具有竞争力的科研启动经费及办公、实验用房,支持受聘者组建相应的科研团队;
3.为青年人才的学术成长提供指导和全方位支持;
4.按照国家和上海市政策提供各类保险和住房公积金(含补充公积金);依托强大的附属医院资源,开通就医绿色通道,提供良好的医疗保健服务。
四、应聘方式
应聘PI岗位者请将下述材料发送至研究院邮箱:(点击查看),请【点击下方“立即投递/投递简历”,即刻进行职位报名】
个人简历(英文);
当前工作介绍及未来工作设想(英文,2-3页);
推荐信(不少于3位推荐者)。
五、联系方式
高老师,021-68382515,(点击查看)
(更多详情请参见官网:https://siti.renji.com:10443/)
Faculty Recruitment at Shanghai Immune Therapy Institute (SITI)
About Shanghai Immune Therapy Institute (SITI)
Located in the center of Shanghai Pudong District, SITI is a newly
established research institute affiliated with Renji Hospital,
Shanghai Jiao Tong University School of Medicine led by world-renowned
immunologist Chen Dong. The institute aims to pursue basic- and clinical-orientated
innovative research in tumor immunotherapy, chronic inflammatory diseases,
transplantation, infectious diseases, and vaccine development. By the year
2035, SITI aims to establish itself as a global leader in research areas
encompassing new drug targets, novel mechanisms, antibody drug development,
immunotherapy, and other significant immune-related diseases.
SITI currently has 10 research groups led by full-time principal
investigators (PIs) recruited from around the world and 8 PIs are national talents
(including national youth talents). As the main member unit of National Key
Laboratory of Innovative Immunotherapy, SITI provides substantial ongoing
support and an open and vibrant environment for scientific research innovation.
Positions
SITI seeks outstanding applicants for a Principal Investigator faculty
position within but not limited to the area of basic Immunology, tumor
immunotherapy, inflammatory diseases, transplantation immunology, Infectious
diseases, vaccine development, and systemic Immunology. We are particularly
seeking candidates who will bring novel approaches, either technical or
conceptual, to the study of the immune system.
Qualifications
Applicants should hold Ph.D. degree or equivalent and have substantial
postdoctoral training with a track record of research excellence. The candidate
is expected to have demonstrated creativity in research and commitment to
equity. Successful candidates will be innovative leaders who can independently
run a research program, advise laboratory trainees and staff, and make
significant scientific achievements.
What we offer
SITI consists of faculty members
with diverse expertise spanning basic and translational immunology
investigation and provides opportunities to turn basic research discoveries
into translational research in close collaboration with clinical partners in Renji Hospital
and other high-level affiliated hospitals.
SITI faculty are supported with
a wide variety of shared core facilities, including state-of-the-art flow
cytometry, confocal microscopy, and computing, etc.
SITI will provide guidance and
all-round support for the academic growth of young talents.
Competitive international
competitive salary package, housing allowance, and research start-up funds
commensurate with the applicant’s academic experience.
Access to benefits and other
provisions per hospital and institutional regulations
Application Instructions
To apply, please submit a single PDF file containing a full CV with a
publication list and the statement of research (both in English) to
(点击查看).
信息来源于网络,如有变更请以原发布者为准。
来源链接:
https://www.shsmu.edu.cn/rlzy/info/1011/3314.htm
附件/来源打开异常提示
附件下载异常:因平台URL协议兼容性原因,公告正文附件材料可能存在无法下载情况,届时您可复制附件链接并新建页面打开查看。
来源链接打开异常:若文中“来源链接XXX”无法正常打开,属内容来源网站异常情况,本平台无法监控处理,如有需求,可持续关注相应链接修复情况。